CA
ARQT icon

Cliff Asness’s Arcutis Biotherapeutics ARQT Stock Holding History

Cliff Asness’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.66M Sell
330,324
-137,929
-29% -$3.21M ﹤0.01% 1660
2026
Q1 		$11M Sell
468,253
-31,165
-6% -$795K 0.01% 1294
2025
Q4 		$14.5M Buy
499,418
+58,103
+13% +$1.49M 0.01% 1052
2025
Q3 		$8.32M Buy
441,315
+66,082
+18% +$1.04M 0.01% 1185
2025
Q2 		$5.26M Buy
375,233
+127,037
+51% +$1.78M ﹤0.01% 1264
2025
Q1 		$3.88M Buy
248,196
+43,716
+21% +$616K ﹤0.01% 1254
2024
Q4 		$2.85M Sell
204,480
-47,671
-19% -$522K ﹤0.01% 1339
2024
Q3 		$2.35M Sell
252,151
-5,206
-2% -$51.4K ﹤0.01% 1426
2024
Q2 		$2.39M Buy
257,357
+226,258
+728% +$2.05M ﹤0.01% 1377
2024
Q1 		$308K Sell
31,099
-257,989
-89% -$1.93M ﹤0.01% 2120
2023
Q4 		$934K Buy
+289,088
New +$786K ﹤0.01% 1632

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Cliff Asness's ARQT Position: Q2 2026 in Review

Cliff Asness reduced its Arcutis Biotherapeutics (ARQT) stake by 29% in Q2 2026, selling an estimated $3.21M and leaving 330,324 shares worth $8.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1660.

Cliff Asness first reported a position in ARQT in Q4 2023 and has held it in 11 quarters since. The position peaked at $14.5M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Cliff Asness held 330,324 shares of Arcutis Biotherapeutics worth $8.66M as of Q2 2026.
  • Cliff Asness sold 137,929 Arcutis Biotherapeutics shares in Q2 2026, an estimated $3.21M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #1660 holding.
  • Cliff Asness first reported a position in Arcutis Biotherapeutics in Q4 2023 and has held it in 11 quarters since.
  • Cliff Asness's Arcutis Biotherapeutics position peaked at $14.5M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.